InterveXion Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Company Type:
Company Website:
Company HQ State:
Arkansas
Company HQ Country:
United States
Year Founded:
2004
Main Therapeutic Focus:
Lead Product in Development:
IXT-m200
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
President & Chief Executive Officer
InterveXion Therapeutics